107 results on '"Hayashi T"'
Search Results
2. Lipid cell change of urothelial carcinoma is a sign of tumor aggressiveness and worst prognosis
3. Contribution of metabolic status to the development of urinary tract stone which required surgical intervention
4. Prediction of adrenal pathology in patients with primary aldosteronism
5. Predictive value and potentials for co-targeted therapy of STAT1 signaling in gemcitabine/cisplatin resistant bladder cancer
6. Parallels between immunohistochemical classification of upper and lower tract urothelial carcinoma using markers of urothelial differentiation
7. Improved prognosis for old-aged patients with metastatic renal cell carcinoma after targeted therapy
8. Serum cytokeratin 19 fragments: A novel useful postoperative prognostic marker in patients with upper urinary tract urothelial carcinoma
9. Accurate clinical T3 staging by a computed tomography scoring system is an independent preoperative predictor of survival in patients with urothelial carcinoma of the ureter
10. PCDHB9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients
11. Lipid cell variant shows worst prognosis among the variants of urothelial carcinoma of the urinary bladder
12. 318 - Longitudinal evaluation of health related quality of life following laparoscopic adrenalectomy: Impact of adrenalectomy on cortisol-producing adenoma
13. Comparisons of surgeons’ and assistants’ fatigue after laparoendoscopic single-site versus conventional laparoscopic adrenalectomy: A single surgeon’s experience
14. Absolute copy number and fragments size of circulating cell-free DNA are useful markers for renal cell carcinoma
15. Extracellular vesicles isolated from human renal cell carcinoma tissues disrupt vascular endothelial cell morphology via azurocidin
16. P139 - Lipid cell change of urothelial carcinoma is a sign of tumor aggressiveness and worst prognosis
17. P080 - Early hyperbaric oxygen therapy improves radiation induced hemorrhagic cystitis and proctitis
18. P128 - Contribution of metabolic status to the development of urinary tract stone which required surgical intervention
19. Her2 alterations in muscle-invasive bladder cancer: There is more than protein expression in patient selection for targeted therapy
20. Longitudinal evaluation of health related quality of life following laparoscopic adrenalectomy: Impact of adrenalectomy on cortisol-producing adenoma
21. T-DM1, a novel HER2 antibody-cytotoxic drug conjugate, has anti-metastatic potential and is a promising targeted therapy for bladder cancer with HER2 IHC score 2+/3+
22. Prognostic impact of immunohistochemical classification of bladder cancer according to luminal (Uroplakin III) and basal (Cytokeratin 5/6) markers
23. PT367 - Accurate clinical T3 staging by a computed tomography scoring system is an independent preoperative predictor of survival in patients with urothelial carcinoma of the ureter
24. 1155 - Improved prognosis for old-aged patients with metastatic renal cell carcinoma after targeted therapy
25. 747 - Prediction of adrenal pathology in patients with primary aldosteronism
26. 742 - Serum cytokeratin 19 fragments: A novel useful postoperative prognostic marker in patients with upper urinary tract urothelial carcinoma
27. 731 - Parallels between immunohistochemical classification of upper and lower tract urothelial carcinoma using markers of urothelial differentiation
28. 260 - PCDHB9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients
29. 174 - Predictive value and potentials for co-targeted therapy of STAT1 signaling in gemcitabine/cisplatin resistant bladder cancer
30. 853 Prevalence of hand joint symptoms of androgen deprivation therapy in Japanese prostate cancer patients
31. 929 Targeting lactate transporters for the treatment of urothelial carcinoma
32. 1070 Regenerating islet-derived related protein 4 as candidate of a novel biomarker in castration-resistant prostate cancer patients
33. 110 Combination therapy using molecular-targeted drugs inhibiting platelet-derived growth factor receptors in the tumor microenvironment of renal cell carcinoma
34. 493 Longitudinal evaluation of patient-reported cosmesis outcome following laparoscopic adrenalectomy: Laparoendoscopic single-site adrenalectomy vs conventional laparoscopic adrenalectomy
35. 925 STAT1 inhibition restored chemotherapy sensitivity in cisplatin/gemcitabine resistant bladder cancer
36. 791 Notch2-HEY axis promotes tumour growth in bladder cancer through cell cycle progression and de-differentiation
37. 121 TSPAN8 expression in renal cell carcinoma is a poor prognostic factor and a novel therapeutic target
38. 79 - Absolute copy number and fragments size of circulating cell-free DNA are useful markers for renal cell carcinoma
39. 78 - Extracellular vesicles isolated from human renal cell carcinoma tissues disrupt vascular endothelial cell morphology via azurocidin
40. 12 - Comparisons of surgeons’ and assistants’ fatigue after laparoendoscopic single-site versus conventional laparoscopic adrenalectomy: A single surgeon’s experience
41. 16 Comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients
42. 758 Minimally-invasive establishment of urological cancer xenografts: A high-precision approach with ultrasound-guidance
43. 530 - Her2 alterations in muscle-invasive bladder cancer: There is more than protein expression in patient selection for targeted therapy
44. 387 - Prognostic impact of immunohistochemical classification of bladder cancer according to luminal (Uroplakin III) and basal (Cytokeratin 5/6) markers
45. 972 - T-DM1, a novel HER2 antibody-cytotoxic drug conjugate, has anti-metastatic potential and is a promising targeted therapy for bladder cancer with HER2 IHC score 2+/3+
46. 522 Targeting HER2 with trastuzumab-DM1 (T-DM1) is highly effective in preclinical models of HER2-overexpressing bladder cancer
47. 39 Notch2 promotes bladder cancer progression: Pre-clinical rationale for a novel targeted therapy
48. 516 Targeting IGF-BP2 and 5 with the bispecific antisense oligodeoxynucleotide OGX-225 in chemoresistant bladder cancer
49. 208 Regenerating islet-derived family, member 4 enhances cell proliferation, castration-resistance and chemoresistance through acceleration of neuroendocrine differentiation in human prostate cancer cells
50. 50 Silencing Notch-1 and Notch-3 promotes epithelial-to-mesenchymal transition (EMT) and self-renewal potential in human bladder cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.